Menopause, GSM, and Recurrent UTIs

Menopause brings a number of changes to the body, including a drop in estrogen. This drop in estrogen contributes to conditions like genitourinary syndrome of menopause (GSM) and recurrent urinary tract infections.

Menopause and Declining Estrogen

Menopause is a natural biological process that marks the end of the female body’s menstrual cycle and reproductive years. The ovaries stop ovulating — or releasing egg cells into the uterus. During this time the body’s hormone levels change. Estrogen and progesterone decline, which can cause a number of downstream effects, including genitourinary syndrome of menopause.

Genitourinary syndrome of menopause (GSM) is the term specialists use to describe the constellation of vulvovaginal, sexual, and urinary changes caused by the drop in estrogen that comes with menopause¹. Before menopause, estrogen stimulates the vaginal lining to produce glycogen, which feeds protective Lactobacillus bacteria found in the vaginal microbiome. Those lactobacilli convert glycogen into lactic acid, keeping the vaginal environment acidic — typically a pH of 3.5–4.5 — an environment that is hostile to the E. coli strains responsible for most urinary tract infections²³.

Unlike hot flashes, GSM does not resolve on its own. It typically gets worse without treatment, and it is thought to affect somewhere between half and the large majority of postmenopausal women, depending on the study, while remaining significantly underdiagnosed¹. Recurrent UTIs are one of its most consequential downstream effects, and, as the new study underscores, not merely an annoyance to be managed with round after round of antibiotics⁴.

The Role of Estrogen in the Urinary Tract

When estrogen falls, the body’s natural, first-line defense system weakens: the vaginal lining thins and becomes more fragile, glycogen production drops, vaginal pH climbs toward neutral or alkaline, lactobacilli are replaced by a more varied and less protective microbial mix, and the urethral and bladder-neck tissue — which shares the same estrogen sensitivity — thins as well²⁵. The net effect is a genitourinary tract with a compromised first line of defense against infection, where bacteria that would once have been naturally outcompeted now have an easier path to colonizing the vagina, ascending the urethra, and reaching the bladder. Pelvic floor changes associated with estrogen loss, like incomplete bladder emptying from prolapse or weakened support, compound the problem further by giving bacteria more time to multiply⁵.

GSM vs. UTI Symptoms

Differentiating between GSM and UTIs can be challenging, especially given the fact that experiencing GSM increases your risk of getting UTIs. They share a number of overlapping symptoms with a few key differences.

GSM Symptoms

Symptoms of GSM may be experienced across the genitourinary tract, including the vagina, the urethra, and the bladder. Vaginal dryness, itching, burning, or irritation may be present. Urinary issues may include frequency and urgency, burning, incontinence, and frequent urinary tract infections. Sexual discomfort may arise due to lack of lubrication during intercourse. Broader chronic pelvic pain is also common¹.

UTI Symptoms

Symptoms of a UTI may consist of urinary frequency, urgency, incontinence, burning, discolored or foul-smelling urine, as well as pelvic pain and pain during intercourse⁶. Unlike GSM, UTIs typically do not cause vaginal symptoms, however both can be present at the same time.

GSM vs. UTI Diagnosis

Differentiating between GSM and UTI is important, as their treatments differ. Visiting a healthcare provider is important, as they will be able to evaluate your symptoms and order diagnostic testing that can aid in determining what the root cause may be.

GSM is diagnosed through a clinical examination in addition to supporting diagnostic tests. Your healthcare provider will evaluate your symptoms, medical history, and conduct a physical examination of the vulva, vagina, and urethra to look for signs of reduced estrogen. In addition, they may also test your vagina’s pH, look at your vaginal cells under a microscope, as well as order urinalysis or urine culture to try to rule out a UTI. Importantly, there is no single laboratory test that will tell you whether or not your symptoms are due to GSM¹⁷.

A UTI is diagnosed based on your symptoms, medical history, and a positive diagnostic test result. Culturing and urinalysis are the most common diagnostics used, though increasingly more advanced tests like those that use next-generation sequencing are leveraged for chronic or complicated UTI cases⁸. Importantly, a true UTI requires urinary symptoms together with a positive diagnostic test⁶. Neither element alone is sufficient.

If no symptoms are present, but bacteria is found in urine, this is considered asymptomatic bacteriuria (ASB) — a separate condition from UTI which is generally not treated with antibiotics, except in specific cases⁹. The urinary tract, like the vagina, has its own community of microbes called the urobiome⁵. Just because bacteria is found in urine does not mean it needs to be treated. In some cases, treating this bacteria may disrupt the urobiome and counterintuitively increase the risk of infection while contributing to the spread of antibiotic resistance⁹¹⁰.

A shorthand that is standard in the field: positive urine test plus symptoms points to a UTI; positive urine test without symptoms is ASB and should be left alone in most cases; symptoms without a positive urine test may point toward a missed infection, GSM, or other non-infectious conditions. It is important to note here, that standard urine culture is a flawed testing technique and often fails, so sometimes testing needs to be repeated or reflexed to an advanced diagnostic test, like the BIOTIA-ID Urine Test⁶¹¹.

For anyone living through this, it is worth trying to control the urge to treat every burning or painful sensation as "another UTI" that you need an antibiotic prescription for. If your symptoms are not actually due to a UTI, an improper use of antibiotics can contribute to the spread of antibiotic resistance. Instead, when symptoms appear, make sure to visit your provider to get evaluated and tested. Getting a culture to inform antibiotic selection is important, and for chronic/complicated UTIs, getting a more advanced, clinical metagenomic test — rather than treating blindly on symptoms alone — is the best way to determine an informed clinical path forward⁶.

GSM vs. UTI Treatment

While interconnected, GSM and UTI have different treatment approaches. UTIs are treated with drugs called antimicrobials, drugs that kill or stop microbes from replicating. Antimicrobials include both antibiotics and antifungals³. On the other hand, GSM is treated progressively depending on symptom severity¹⁷. This may include the use of vaginal moisturizers or lubricants, low-dose vaginal estrogen, and supportive approaches like pelvic floor therapy. In exciting news, new research is providing additional evidence that treating GSM through low-dose vaginal estrogen can not only reduce the symptoms of GSM, it can also reduce the risk of recurrent UTIs⁴¹².

GSM Treatment Guidelines

In 2025, the American Urological Association, together with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) and the American Urogynecologic Society (AUGS), released a comprehensive joint guideline on GSM⁷. Among its recommendations: clinicians should recommend low-dose vaginal estrogen for patients with GSM and recurrent UTIs specifically to reduce the risk of future infections — a recommendation grounded in randomized trials and systematic reviews that predate a new 2026 database study that now adds additional data behind it¹²¹³.

Treatment options generally include¹⁷:

• Low-dose vaginal estrogen — a cream, a small vaginal tablet, or a slow-release ring
• Vaginal DHEA (prasterone), a non-estrogen hormonal option that is converted to estrogen and androgen locally within the vaginal tissue.
• Ospemifene, an oral medication that acts like estrogen in vaginal tissue without being estrogen itself.
• Vaginal moisturizers and lubricants, useful for comfort but not a substitute for hormonal therapy when it comes to reducing infection risk.

An important distinction: these are mostly local, not systemic, therapies. Vaginal estrogen is delivered directly to the tissue that needs it, with minimal absorption into the bloodstream, carrying lower risk as compared to oral or transdermal systemic hormone therapy¹¹³.

In 2025, the FDA began a major revision of menopausal hormone therapy labeling, removing long-standing boxed warnings from most estrogen-containing products and formally distinguishing low-dose vaginal estrogen as a locally acting therapy with a different safety profile. That relabeling only recently caught up to what specialty guidelines had already concluded, and many prescribers — and patients — are still catching up to the relabeling itself.

For women with a history of hormone-sensitive breast cancer, decisions here are more nuanced and should involve both a gynecologist and an oncologist, though research increasingly supports vaginal estrogen as worth discussing even in this population given its minimal systemic absorption¹⁴.

GSM, Vaginal Estrogen, and Recurrent UTIs

A recent study published in Urology supports what menopause specialists have argued for years: undertreated recurrent UTIs in postmenopausal women are not just uncomfortable — they can be deadly. And low-dose vaginal estrogen therapy could prevent a meaningful share of recurrent UTI-associated deaths, despite only about 5% of eligible women receiving a prescription for it⁴.

The research, by Justin LaClair and colleagues, used the Epic Cosmos database — a collaboration of electronic health record data spanning hundreds of millions of patient records across U.S. health systems — to identify nearly two million women with recurrent UTIs, defined as two separately coded UTIs within one to six months of each other. The researchers split these women into two groups: those who received a vaginal estrogen prescription within two months of their second UTI, and those who never received one. Both groups were then analyzed for eight years to track three serious outcomes: sepsis, hospital admission, and death.

The results were striking, particularly for older women. Among women aged 55–69, roughly 7.3% of those who never received vaginal estrogen died within eight years, compared with about 1.5% of those who did — a reduction on the order of 60–80% in the odds of death over that period. Hospitalization rates followed a similar pattern in older women, with vaginal estrogen use associated with meaningfully lower admission rates. The protective association was concentrated in older postmenopausal women; among women under 55, the differences in sepsis and mortality outcomes were not statistically significant, which fits with the biological story — estrogen deficiency, and its effect on the urinary tract, deepens with time following menopause.

Perhaps the most important number in the paper is not about outcomes at all — it is about access. Despite low-dose vaginal estrogen being a specialty-society guideline recommendation for exactly this population, only around 5% of women with recurrent UTIs in the dataset had actually been prescribed it. A likely contributing factor to this prescription gap are the now outdated warnings on estrogen-containing therapies by the FDA. With the warnings removed, providers may be more inclined to prescribe low-dose vaginal estrogen to their patients.

It is important to note, this is a retrospective, real-world database analysis, not a randomized controlled trial — women who get prescribed vaginal estrogen may differ from those who do not in ways the analysis cannot fully account for (access to care, engagement with a menopause-literate clinician, overall health status), and an editorial comment accompanying the paper, from Dr. Sara Lenherr and Dr. Rachel Rubin, addressed exactly this kind of nuance¹⁵.

Association is not the same as proof of causation. But this analysis does not stand alone — it adds a large, real-world dataset on top of decades of smaller randomized trials and systematic reviews that already established, via a study design built to isolate cause and effect, that local vaginal estrogen reduces UTI recurrence. What the new study adds is scale, and a look at outcomes further downstream than "did the infection come back" — outcomes that are much harder to shrug off.

Hope For the Chronic UTI Community

Among people who live with recurrent UTIs — and among the clinicians and communities built around supporting them — the study by LaClair et al. has been circulating fast, and for good reason. Menopause and sexual-health specialists have been sharing it directly with their audiences: urologist Dr. Rachel Rubin called it out plainly to colleagues, noting the guideline recommendation has existed for a while and yet prescribing has not caught up, while menopause specialist Dr. Lauren Streicher flagged the same headline numbers to her readers under a title that does not mince words about the stakes¹⁵.

Part of why this resonates so specifically with the chronic UTI community is that it validates something many patients have said for years and have not always been believed about: that recurrent UTIs are not a minor inconvenience to be waited out between antibiotic courses, but a condition that can escalate to genuinely dangerous territory. Many women with a long history of recurrent UTIs describe being told their symptoms were "just anxiety", "just aging", or that a negative urine culture meant nothing was wrong — even while they kept experiencing UTI symptoms. A study of this size, showing a measurable mortality difference tied to a specific, fixable gap in care, gives that lived experience some hard, quantified backing.

It also reframes the conversation that chronic UTI patients often have to have with new providers. Instead of arguing for vaginal estrogen as a "nice to have" for comfort, patients and their advocates now have a large real-world dataset to point to that ties the therapy to hospitalization and mortality outcomes — the kind of evidence that tends to move clinical practice, and the kind of evidence patients can bring into an appointment when a therapy they have been asking about has not been seriously considered.

The Takeaway

If you are peri- or postmenopausal and dealing with UTIs that keep coming back, this new evidence is a good reason to raise the topic directly with your doctor — not just to treat the current infection, but to ask specifically whether low-dose vaginal estrogen or another local hormonal therapy is appropriate for you. This is not an experimental or fringe idea. It is a formal recommendation from major urology and urogynecology societies, and the newest evidence suggests the stakes of skipping it may be higher than "just another round of antibiotics" — particularly for women past the earlier stretch of postmenopausal life, where this large real-world study found the difference in serious outcomes was most pronounced⁷.

Menopause changes a lot about the body in ways that do not get much attention. The link between estrogen, urinary tract health, and the risk of serious infection is one of those under-discussed changes — but as this new research suggests, it is also one of the more treatable ones, once it is actually named and acted on⁴.